Cargando…
Sphingosine-1-Phosphate and Its Signal Modulators Alleviate Psoriasis-Like Dermatitis: Preclinical and Clinical Evidence and Possible Mechanisms
BACKGROUND: Psoriasis is an autoimmune skin disease associated with lipid metabolism. Sphingosine-1-phosphate (S1P) is a bioactive lipid that plays a key role in the development of autoimmune diseases. However, there is currently a lack of comprehensive evidence of the effectiveness of S1P on psoria...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724303/ https://www.ncbi.nlm.nih.gov/pubmed/34992595 http://dx.doi.org/10.3389/fimmu.2021.759276 |
_version_ | 1784625893607473152 |
---|---|
author | Liu, Liu Wang, Jiao Li, Hong-jin Zhang, Shuo Jin, Meng-zhu Chen, Si-ting Sun, Xiao-ying Zhou, Ya-qiong Lu, Yi Yang, Dan Luo, Ying Ru, Yi Li, Bin Li, Xin |
author_facet | Liu, Liu Wang, Jiao Li, Hong-jin Zhang, Shuo Jin, Meng-zhu Chen, Si-ting Sun, Xiao-ying Zhou, Ya-qiong Lu, Yi Yang, Dan Luo, Ying Ru, Yi Li, Bin Li, Xin |
author_sort | Liu, Liu |
collection | PubMed |
description | BACKGROUND: Psoriasis is an autoimmune skin disease associated with lipid metabolism. Sphingosine-1-phosphate (S1P) is a bioactive lipid that plays a key role in the development of autoimmune diseases. However, there is currently a lack of comprehensive evidence of the effectiveness of S1P on psoriasis. OBJECTIVE: To assess the efficacy and possible mechanism of S1P and its signal modulators in the treatment of psoriasis-like dermatitis. METHODS: Six databases were searched through May 8, 2021, for studies reporting S1P and its signal modulators. Two reviewers independently extracted information from the enrolled studies. Methodological quality was assessed using SYRCLE’s risk of bias tool. RevMan 5.3 software was used to analyze the data. For clinical studies, the Psoriasis Area and Severity Index score were the main outcomes. For preclinical studies, we clarified the role of S1P and its regulators in psoriasis in terms of phenotype and mechanism. RESULTS: One randomized double-blind placebo-controlled trial and nine animal studies were included in this study. The pooled results showed that compared with control treatment, S1P receptor agonists [mean difference (MD): −6.80; 95% confidence interval (CI): −8.23 to −5.38; p<0.00001], and sphingosine kinase 2 inhibitors (MD: −0.95; 95% CI: −1.26 to −0.65; p<0.00001) alleviated psoriasis-like dermatitis in mice. The mechanism of S1P receptor agonists in treating psoriasis might be related to a decrease in the number of white blood cells, topical lymph node weight, interleukin-23 mRNA levels, and percentage of CD3(+) T cells (p<0.05). Sphingosine kinase 2 inhibitors ameliorated psoriasis in mice, possibly by reducing spleen weight and cell numbers (p<0.05). CONCLUSIONS: S1P receptor agonists and sphingosine kinase 2 inhibitors could be potential methods for treating psoriasis by decreasing immune responses and inflammatory factors. |
format | Online Article Text |
id | pubmed-8724303 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87243032022-01-05 Sphingosine-1-Phosphate and Its Signal Modulators Alleviate Psoriasis-Like Dermatitis: Preclinical and Clinical Evidence and Possible Mechanisms Liu, Liu Wang, Jiao Li, Hong-jin Zhang, Shuo Jin, Meng-zhu Chen, Si-ting Sun, Xiao-ying Zhou, Ya-qiong Lu, Yi Yang, Dan Luo, Ying Ru, Yi Li, Bin Li, Xin Front Immunol Immunology BACKGROUND: Psoriasis is an autoimmune skin disease associated with lipid metabolism. Sphingosine-1-phosphate (S1P) is a bioactive lipid that plays a key role in the development of autoimmune diseases. However, there is currently a lack of comprehensive evidence of the effectiveness of S1P on psoriasis. OBJECTIVE: To assess the efficacy and possible mechanism of S1P and its signal modulators in the treatment of psoriasis-like dermatitis. METHODS: Six databases were searched through May 8, 2021, for studies reporting S1P and its signal modulators. Two reviewers independently extracted information from the enrolled studies. Methodological quality was assessed using SYRCLE’s risk of bias tool. RevMan 5.3 software was used to analyze the data. For clinical studies, the Psoriasis Area and Severity Index score were the main outcomes. For preclinical studies, we clarified the role of S1P and its regulators in psoriasis in terms of phenotype and mechanism. RESULTS: One randomized double-blind placebo-controlled trial and nine animal studies were included in this study. The pooled results showed that compared with control treatment, S1P receptor agonists [mean difference (MD): −6.80; 95% confidence interval (CI): −8.23 to −5.38; p<0.00001], and sphingosine kinase 2 inhibitors (MD: −0.95; 95% CI: −1.26 to −0.65; p<0.00001) alleviated psoriasis-like dermatitis in mice. The mechanism of S1P receptor agonists in treating psoriasis might be related to a decrease in the number of white blood cells, topical lymph node weight, interleukin-23 mRNA levels, and percentage of CD3(+) T cells (p<0.05). Sphingosine kinase 2 inhibitors ameliorated psoriasis in mice, possibly by reducing spleen weight and cell numbers (p<0.05). CONCLUSIONS: S1P receptor agonists and sphingosine kinase 2 inhibitors could be potential methods for treating psoriasis by decreasing immune responses and inflammatory factors. Frontiers Media S.A. 2021-12-21 /pmc/articles/PMC8724303/ /pubmed/34992595 http://dx.doi.org/10.3389/fimmu.2021.759276 Text en Copyright © 2021 Liu, Wang, Li, Zhang, Jin, Chen, Sun, Zhou, Lu, Yang, Luo, Ru, Li and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Liu, Liu Wang, Jiao Li, Hong-jin Zhang, Shuo Jin, Meng-zhu Chen, Si-ting Sun, Xiao-ying Zhou, Ya-qiong Lu, Yi Yang, Dan Luo, Ying Ru, Yi Li, Bin Li, Xin Sphingosine-1-Phosphate and Its Signal Modulators Alleviate Psoriasis-Like Dermatitis: Preclinical and Clinical Evidence and Possible Mechanisms |
title | Sphingosine-1-Phosphate and Its Signal Modulators Alleviate Psoriasis-Like Dermatitis: Preclinical and Clinical Evidence and Possible Mechanisms |
title_full | Sphingosine-1-Phosphate and Its Signal Modulators Alleviate Psoriasis-Like Dermatitis: Preclinical and Clinical Evidence and Possible Mechanisms |
title_fullStr | Sphingosine-1-Phosphate and Its Signal Modulators Alleviate Psoriasis-Like Dermatitis: Preclinical and Clinical Evidence and Possible Mechanisms |
title_full_unstemmed | Sphingosine-1-Phosphate and Its Signal Modulators Alleviate Psoriasis-Like Dermatitis: Preclinical and Clinical Evidence and Possible Mechanisms |
title_short | Sphingosine-1-Phosphate and Its Signal Modulators Alleviate Psoriasis-Like Dermatitis: Preclinical and Clinical Evidence and Possible Mechanisms |
title_sort | sphingosine-1-phosphate and its signal modulators alleviate psoriasis-like dermatitis: preclinical and clinical evidence and possible mechanisms |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724303/ https://www.ncbi.nlm.nih.gov/pubmed/34992595 http://dx.doi.org/10.3389/fimmu.2021.759276 |
work_keys_str_mv | AT liuliu sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms AT wangjiao sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms AT lihongjin sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms AT zhangshuo sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms AT jinmengzhu sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms AT chensiting sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms AT sunxiaoying sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms AT zhouyaqiong sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms AT luyi sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms AT yangdan sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms AT luoying sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms AT ruyi sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms AT libin sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms AT lixin sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms |